GE Healthcare has introduced its SenoBright contrast-enhanced spectral mammography (CESM) technology, which uses x-rays at multiple energies to create two separate exposures.
Working like the multiple-flash, red-eye reduction function in a digital camera, CESM’s resulting images illuminate areas where there is angiogenesis, potentially related to the presence of cancer, according to GE.
The product development was carried out in collaboration between GE and Qatar Science & Technology Park—of which the goal is to develop new technologies for aiding in the diagnosis of breast cancer using new developments in digital mammography.
The company noted that the SenoBright option cannot be put into service until it has been made to comply with CE marking. Also, the SenoBright option is not cleared or approved by the FDA.